Restenosis/re-occlusion remains a frequent complication in the first year after percutaneous transluminal angioplasty (PTA). In this study, association of nuclear receptor related 1 protein (Nurr1) haplotypes to the restenosis/re-occlusion rate after femoropopliteal PTA was investigated. Patients (n ¼ 142) with disabling claudication or critical limb ischaemia, who had undergone technically successful femoropopliteal PTA, were prospectively followed up by vascular ultrasound imaging 12 months after the procedure. Nurr1 haplotypes 2 and 3 were associated significantly with the restenosis/re-occlusion rate (adjusted odds ratio 1.6, 95% confidence interval (CI) 1.1e2.3 and 2.0, 1.3e2.8, respectively) on univariate analysis.
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Percutaneous transluminal angioplasty (PTA) is an established method for treatment of peripheral artery disease. However, in up to 50% of patients restenosis/re-occlusion remains a frequent complication occurring in the first year after PTA.
1 Our understanding of the mechanisms of restenosis/re-occlusion is incomplete and inflammation is one of several factors affecting the patency of the arterial segment after successful PTA. 2 Recently, regulation of the inflammation through the nuclear receptor related 1 protein (Nurr1) has been associated with restenosis.
3 Therefore, in this study the association of Nurr1 haplotypes to the risk of restenosis/re-occlusion after femoropopliteal PTA was investigated.
Report
A total of 142 patients (58 women and 84 men aged 69 AE 11 years) with disabling claudication or critical limb ischaemia were enrolled after technically successful femoropopliteal PTA and were followed up by vascular ultrasound imaging at 1, 6 and 12 months. Adverse outcome of PTA (restenosis of !50% of the affected arterial region or re-occlusion determined by the absence of Doppler flow signal) occurred in 85 (60%) patients. Patients with restenosis/ re-occlusion did not differ from patients with successful PTA in risk factors or Fontaine classification.
DNA was extracted from blood samples and Nurr1 single-nucleotide polymorphisms SNP A (rs1466408), Nurr1 SNP B (rs13428968) and Nurr1 SNP C (rs12803) were determined by real-time polymerase chain reaction with appropriate primers and TaqMan Ò probes. Nurr1 haplotypes were reconstructed as described earlier.
3
The presence of rare alleles of Nurr1 SNP B and SNP C was significantly associated with restenosis/re-occlusion rate compared with patients carrying the common alleles (hazard ratio of 1.54, 95% confidence interval (CI) 1.06e3.51 and 2.04, 95% CI 1.17e4.37, respectively); Fig. 1 .
Haplotype 1e4 frequencies were: 49.4%, 23.3%, 19.7% and 6.6%, respectively. Haplotypes 2 and 3 significantly increased the restenosis/re-occlusion rate (relative risks adjusted for sex, age and Fontaine classification calculated by Cox regression were 1.6 (95% CI 1.1e2.3) and 2.0 (95% CI 1.3e2.8), respectively).
Discussion
In our study restenosis/re-occlusion occurred in 85/142 (60%) patients during the 12-month follow-up period after PTA, which is comparable to the published data, 4 and there was a significant association between Nurr1 haplotypes 2 and 3 and the restenosis/re-occlusion rate, on univariate analysis. Nurr1 haplotypes have so far been associated with coronary in-stent restenosis risk in patients undergoing percutaneous coronary intervention. 3 We were not able to confirm an increased risk of restenosis/re-occlusion in patients with haplotype 4 in contrast to the findings of Bonta et al., 3 probably due to the small number of patients with this haplotype (<7%). However, our results indicate that more detailed assessment of the role of Nurr1 variants in restenosis after PTA, in larger studies, is warranted.
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